PT  - JOURNAL ARTICLE
AU  - Serena Verdi
AU  - Seyed Mostafa Kia
AU  - Keir Yong
AU  - Duygu Tosun
AU  - Jonathan M. Schott
AU  - Andre F. Marquand
AU  - James H. Cole
AU  - the Alzheimer’s Disease Neuroimaging Initiative
TI  - Revealing Individual Neuroanatomical Heterogeneity in Alzheimer’s Disease
AID  - 10.1101/2022.06.30.22277053
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.30.22277053
4099  - http://medrxiv.org/content/early/2022/07/03/2022.06.30.22277053.short
4100  - http://medrxiv.org/content/early/2022/07/03/2022.06.30.22277053.full
AB  - Alzheimer’s disease is clinically heterogeneous, in symptom profiles, progression rates and outcomes. This clinical heterogeneity is linked to underlying neuroanatomical heterogeneity. To explore this, we employed the emerging technique of neuroanatomical normative modelling to index regional patterns of variability in cortical thickness in individual patients from the large multi-site Alzheimer’s Disease Neuroimaging Initiative. We aimed to characterise individual differences and outliers in cortical thickness in patients with Alzheimer’s disease, people with mild cognitive impairment and cognitively normal controls. Furthermore, we assessed the relationships between cortical thickness heterogeneity and cognitive function, amyloid-beta, tau, ApoE genotype. Finally, we examined whether individual neuroanatomical normative maps were predictive of conversion from mild cognitive impairment to diagnosed Alzheimer’s disease. Data on cortical thickness from the 148 brain regions of the Destrieux FreeSurfer atlas was obtained from T1-weighted MRI scans of 1492 participants scanned at 62 different sites. A neuroanatomical normative model was developed to index normal cortical thickness distributions using a separate healthy reference dataset (n= 33,072), employing hierarchical Bayesian regression to predict cortical thickness per region using age and sex. These regional normative models were then fine-tuned to the ADNI dataset after which cortical thickness z-scores per region were calculated, resulting in a z-score ‘map’ for each participant. Regions with z-scores < -1.96 were classified as outliers. Patients with Alzheimer’s disease had a median of 12 outlier regions out of a possible 148. Individual patterns of outlier regions were highly variable, with the highest overlap in the parahippocampal gyrus at only 47% of patients. For 62 regions, over 90% of these patients had cortical thicknesses within the normal range. Patients with Alzheimer’s disease had significantly more outlier regions than people with mild cognitive impairment or controls [F(2, 1022) = 95.39), P = 2.0 x ×10−16]. They were also statistically more dissimilar to each other than were people with mild cognitive impairment or cognitive normal controls [F(2, 1024) = 209.42, P = 2.2×10−16]. Having a greater number of outlier regions was associated with worse cognitive function, CSF protein concentrations and an increased risk of converting from mild cognitive impairment to Alzheimer’s disease within three years (HR =1.028, 95% CI[1.016,1.039], P =1.8 ×10−16). Individualised normative maps of cortical thickness highlight the heterogeneity of Alzheimer’s effects on the brain. Regional outlier estimates have the potential to be a marker of disease and could be used to track an individual’s disease progression or treatment response in clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the EPSRC-funded UCL Centre for Doctoral Training in Intelligent, Integrated Imaging in Healthcare (i4health) (EP/S021930/1) and the Department of Health's National Institute for Health Research funded University College London Hospitals Biomedical Research Centre. In addition, A.F.M. gratefully acknowledges funding from the Dutch Organization for Scientific Research via a VIDI fellowship (grant number 016.156.415); J.M.S. acknowledges the support of Alzheimer's Research UK, Brain Research UK, Weston Brain Institute, Medical Research Council and the British Heart Foundation. K.Y. is an Etherington PCA Senior Research Fellow and is funded by the Alzheimer's Society, grant number 453 (AS-JF-18-003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that are located at: https://adni.loni.usc.edu/methods/documents/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStatistical analysis scripts are available on GitHub (https://github.com/serenaverdi/ADNI_normative-modelling). The neuroanatomical normative model was generated using the PCNtoolkit software package (https://github.com/amarquand/PCNtoolkit). ADNI data used in this study are publicly available and can be requested following ADNI Data Sharing and Publications Committee guidelines: http://adni.loni.usc.edu/data-samples/access-data/ADNI =Alzheimer’s Disease Neuroimaging Initiative;AD =Alzheimer’s disease;ApoE =Apolipoprotein E;CSF=Cerebrospinal fluid;CN =cognitively normal;MCI =Mild Cognitive impairment;MMSE=Mini-Mental State Examination